Caribou Biosciences, Inc.
CRBUCaribou Biosciences is a clinical-stage biopharmaceutical company specializing in the development of allogeneic, or off-the-shelf, CAR-T cell therapies using its proprietary chRDNA genome-editing platform.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Caribou Biosciences is a clinical-stage biopharmaceutical company specializing in the development of allogeneic, or off-the-shelf, CAR-T cell therapies using its proprietary chRDNA genome-editing platform. The company's core value proposition lies in its ability to create more precise genome edits that enhance the activity and durability of cell therapies for patients with hematologic malignancies. By utilizing healthy donor cells, Caribou aims to provide rapid patient treatment and broader access compared to traditional autologous therapies.
A pioneer in CRISPR hybrid RNA-DNA (chRDNA) technology, positioning itself as a next-generation alternative to autologous CAR-T and bispecific antibody therapies.
Questions, answered.
- What is Caribou Biosciences, Inc.'s market cap?
- Caribou Biosciences, Inc. (CRBU) has a market capitalization of $157.7M and trades on NASDAQ.
- Who are Caribou Biosciences, Inc.'s competitors?
- Caribou Biosciences, Inc.'s key competitors include Allogene Therapeutics, CRISPR Therapeutics, Beam Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Caribou Biosciences, Inc. partner with?
- Caribou Biosciences, Inc.'s notable partners include Memorial Sloan Kettering Cancer Center, AbbVie, Intellia Therapeutics.
- Where is Caribou Biosciences, Inc. headquartered?
- Caribou Biosciences, Inc. is headquartered in United States of America and employs approximately 137 people. It has been publicly traded since 2021.